index_ph001

Daiichi Sankyo names Antoine Yver global head of oncology research and development

pharmafile | April 1, 2016 | Appointment | Business Services, Medical Communications Daiichi Sankyo, Japan, appointment 

Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April 1, 2016.

In this newly created role, Yver will report to Glenn Gormley, senior executive officer and global head, research & development, Daiichi Sankyo and chairman of Daiichi Sankyo Inc.

Glenn Gormley says: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.”

Yver joins Daiichi Sankyo from AstraZeneca (LSE: ANZ), where he most recently served as senior vice president and head of oncology, global medicines development, and global medicines development China lead across all therapeutic areas.

Prior to joining AstraZeneca in 2009, he held several international oncology drug development positions at Merck/ Schering-Plough, Johnson & Johnson and Rhône-Poulenc Rorer/ Aventis.

Yver says: “I’m excited to join such a respected company and further build its presence in this important field. I have been most impressed by the quality of science at Daiichi Sankyo and the company’s strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”

 

Related Content

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …

Latest content